CAJ | 학술논문

近年来,胰高血糖素样肽-1类降糖药物的胰腺安全性引起了广泛关注,主要是因为其可能促进急性胰腺炎的发生,诱发与慢性胰腺炎相关的组织学改变,远期还可能诱发胰腺癌.流行病学研究和基础研究中存在一些相互矛盾的研究数据,其中的一些研究问题不容被忽视.因此,对现有的研究资料进行回顾和分析可为后续研究的开展和问题的阐明奠定基础.
근년래,이고혈당소양태-1류강당약물적이선안전성인기료엄범관주,주요시인위기가능촉진급성이선염적발생,유발여만성이선염상관적조직학개변,원기환가능유발이선암.류행병학연구화기출연구중존재일사상호모순적연구수거,기중적일사연구문제불용피홀시.인차,대현유적연구자료진행회고화분석가위후속연구적개전화문제적천명전정기출.
There has been a debate over the pancreatic safety of glucagon-like peptide-1-based hypoglycemic therapies in recent years,especially about their potential to promote acute pancreatitis,cause histological changes related to chronic pancreatitis,and possibly,in the long run,induce pancreatic cancer.Clearly conflicting data exist between epidemiologic studies and basic studies,some of which cannot be ignored.Therefore,a full summary and analysis of these studies will lay the foundation for the future investigation.